The NK-92 cell line is an IL-2-dependent natural killer (NK) cell line derived from the peripheral blood mononuclear cells of a 50-year-old Caucasian male with aggressive non-Hodgkin's lymphoma. The NK-92MI cell line is an IL-2-independent NK cell line derived from NK-92 through transfection. The parental NK-92 cells were transformed using the retroviral MFG-hIL-2 vector carrying human IL-2 cDNA via microsomal gene transfer. The transformation is likely stable due to the integration of the vector into the genomic DNA. This cell line exhibits cytotoxicity against many malignant cells; chromium release assays have shown that it can kill K562 and Daudi cells. The NK-92 cells are positive for the following surface markers: CD2, CD7, CD11a, CD28, CD45, and CD54; and negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34, and HLA-DR. Both the parental IL-2-dependent NK-92 cell line and another IL-2-independent variant derived from NK-92, known as NK-92CI, are available from ATCC. Both variants, NK-92MI and NK-92CI, contain, express, and synthesize hIL-2 cDNA. The NK-92MI cell line synthesizes higher levels of IL-2 compared to NK-92CI, whereas the parental cells do not produce or express IL-2.